Tristel (AIM: TSTL) – brilliant results and all is looking good
The manufacturer of infection prevention, contamination control and hygiene products has announced terrific interim results for the six months ended 31 December 2014.
Revenue was up 15% to £7.4m including international sales up 26% to £2.4m, pre-tax profit before share based payments up 57% to £1.1m and basic EPS up 85% to 1.91p.
The Group finished the period with net cash of £2.9m (2013: £1.5m)
Tristel’s lead technology is a proprietary Chlorine dioxide formulation addressing three distinct markets:
- The Human Healthcare market (hospital infection prevention - via the Tristel brand)
- The Contamination…
Previous article Next article
